Clinical trials: Sexual Desire Disorder
Sexual Desire Disorder
An Exploratory Investigation to Identify if Dame Product's "DLM" Works to Improve Sexual Desire and Mood in Females
This is a single-group, non-randomized, non-controlled, open-label observational trial to study and evaluate the efficacy of a commercial dietary supplement, called "DLM" ("test product").
- Trial name
- NCT05130411
- Testing
- DLM - Test product
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Dame Products, Inc.
Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction
BP101 for Adults With Female Sexual Dysfunction
This study is to confirm efficacy and safety of study drug BP101 in female patients with with decrease or loss of sexual desire, which is equal to acquired generalized hypoactive sexual desire disorder (HSDD).
- Conditions
- Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, Sexual Desire Disorder
- Trial name
- NCT03463707
- Testing
- BP101
- Where
- 20 sites in Russia
- Volunteers
- 205 people
- Sponsor
- Ivix LLX
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Naturally Menopausal Women With Low Libido
This study is designed to evaluate efficacy and safety of a testosterone patch as treatment for low libido in naturally menopausal women who are taking estrogen or estrogen/progestin therapy.
- Trial name
- NCT00338312
- Testing
- Testosterone Transdermal System
- Where
- United States
- Volunteers
- 610 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
A Pharmacokinetic (PK) Study to Compare the Absorption of Two Formulations of Transdermal Testosterone Spray and Intrinsa®
The purpose of this study is to determine if the absorption of the testosterone spray is the same as the Intrinsa® Patch.
- Trial name
- NCT01096329
- Testing
- Testosterone Spray 5% and 1%, Intrinsa® Patch and Testosterone Spray 5%, Intrinsa® Patch and Testosterone Spray 1%
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- VIVUS LLC
Sexual Dysfunctions, Psychological
Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
The object of this trial is to assess the safety and efficacy of a 24 week course of flibanserin for the treatment of hypoactive sexual desire disorder in premenopausal women.
- Trial name
- NCT00996164
- Testing
- Flibanserin
- Where
- 75 sites in United States
- Volunteers
- 1,090 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)
This trial examines the way flibanserin is metabolized in postmenopausal women with Hypoactive Sexual Desire Disorder.
- Trial name
- NCT01188603
- Testing
- flibanserin 100 mg dose every evening
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunction, Psychological
Zestra in Women With Mixed Sexual Dysfunction
The objective of this study is to evaluate the clinical efficacy and safety of Zestra(TM) in women with acquired mixed desire/interest/arousal/orgasm disorders under conditions of home usage.
- Trial name
- NCT00118495
- Testing
- Non-prescription Zestra(TM): patented formulation
- Where
- 13 sites in United States
- Volunteers
- 200 people
- Sponsor
- QualiLife Pharmaceuticals
Sexual Dysfunctions, Psychological
Study of Pharmacological Treatment in Women With Female Sexual Interest/Arousal Disorder (FSIAD).
This clinical trial is a prospective, randomized, double-blind Phase III study with two arms to determine the efficacy and safety of the use of an IPDE in women with FSIAD.
- Trial name
- FSIAD (NCT04433559)
- Testing
- Tadalafil 1,5 mg oral tablets
- Volunteers
- 80 people
- Sponsor
- Lidia Larrañaga
Female Sexual Arousal Disorder, Hypoactive Sexual Desire Disorder
Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder
This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal…
- Trial name
- NCT01382719
- Testing
- bremelanotide
- Where
- 68 sites in United States, Canada
- Volunteers
- 612 people
- Sponsor
- Palatin Technologies, Inc
Sexual Dysfunctions, Psychological
Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.
- Trial name
- NCT00996372
- Testing
- flibanserin
- Where
- 75 sites in United States
- Volunteers
- 949 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
A Phase 3, Bridging, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (With or Without Decreased Arousal)
The purpose of this study is to Evaluate the Efficacy and Safety of Subcutaneously Administered Bremelanotide in Premenopausal Women with Hypoactive Sexual Desire Disorder(with or without Decreased Arousal).
- Trial name
- NCT04943068
- Testing
- Bremelanotide
- Where
- South Korea
- Volunteers
- 193 people
- Sponsor
- Kwang Dong Pharmaceutical co., ltd.
Hypoactive Sexual Desire Disorder
1. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an optional Open-label Extension to evaluate the efficacy of bremelanotide (BMT), administered subcutaneously (SC) on an as needed basis for the…
- Trial name
- HSDD (NCT02333071)
- Testing
- Bremelanotide
- Where
- 91 sites in United States, Canada
- Volunteers
- 723 people
- Sponsor
- Palatin Technologies, Inc
Hypoactive Sexual Desire Disorder
Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women
This study is a randomized, double-blind, placebo-controlled, adaptive design, multi-center study of the long-term cardiovascular and breast safety of LibiGel in the treatment of HSDD in postmenopausal women with at least two…
- Trial name
- BLOOM (NCT00612742)
- Testing
- testosterone gel
- Where
- 149 sites in United States, Canada
- Volunteers
- 3,656 people
- Sponsor
- BioSante Pharmaceuticals
Hypoactive Sexual Desire Disorder
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
- Trial name
- NCT00467259
- Testing
- Testosterone Transdermal System
- Where
- 115 sites in United States
- Volunteers
- 1,271 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
The objective of this study is to evaluate the persistence of benefit of LibiGel (testosterone gel) 300 mcg/day compared to placebo gel in a 12 week post-treatment period of Hypoactive Sexual Desire Disorder (HSDD) in surgically…
- Trial name
- NCT01235754
- Testing
- transdermal testosterone gel 1%
- Where
- 102 sites in United States, Canada
- Volunteers
- 626 people
- Sponsor
- BioSante Pharmaceuticals
Hypoactive Sexual Desire Disorder (HSDD)
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) - Second Study
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
- Trial name
- NCT03619005
- Testing
- Prasterone 6.5 mg (0.50%) Vaginal Insert
- Where
- 10 sites in United States
- Sponsor
- EndoCeutics Inc.
Sexual Dysfunctions, Psychological
Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder
Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens
- Trial name
- NCT00601367
- Testing
- flibanserin flexible dose
- Where
- 68 sites in Austria, Belgium and 10 more
- Volunteers
- 480 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Sexual Dysfunctions, Psychological
A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).
To determine if long-term treatment with Flibanserin is safe and to monitor the effectiveness of Flibanserin in Women with HSDD that have already completed a previous study (511.70/71/.74/.75/.105) with Flibanserin.
- Trial name
- NCT00441558
- Testing
- Flibanserin
- Where
- 196 sites in United States, Canada
- Volunteers
- 1,723 people
- Sponsor
- Sprout Pharmaceuticals, Inc
Hypoactive Sexual Desire Disorder
Study of Transdermal Testosterone Patches in Menopausal Women With Low Libido
This study is designed to evaluate the efficacy and safety of 2 doses of the transdermal testosterone patch in naturally or surgically menopausal women with low libido who are not receiving systemic estrogen or estrogen progestin…
- Trial name
- NCT00131495
- Testing
- Testosterone (transdermal patches)
- Where
- Australia
- Volunteers
- 814 people
- Sponsor
- Warner Chilcott
Hypoactive Sexual Desire Disorder
Prasterone (DHEA) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)
The primary objective is to confirm the efficacy of intravaginal prasterone (DHEA) on Hypoactive Sexual Desire Disorder (HSDD) in postmenopausal women.
- Trial name
- NCT03287232
- Testing
- Prasterone 6.5 mg (0.50%) Vaginal Insert
- Where
- 69 sites in United States, Canada
- Volunteers
- 653 people
- Sponsor
- EndoCeutics Inc.